These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2948607)

  • 21. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Goserelin--a new form of hormone therapy in ovarian cancer].
    Vavra N; Barrada M; Fitz R; Sevelda P; Baur M; Dittrich C
    Gynakol Rundsch; 1990; 30 Suppl 1():61-3. PubMed ID: 2150400
    [No Abstract]   [Full Text] [Related]  

  • 24. Selected advances in therapy of urologic cancer--luteinizing hormone releasing hormone (LHRH) and biologic response modifier (BUR).
    Javadpour N
    Prog Clin Biol Res; 1988; 277():27-38. PubMed ID: 2973069
    [No Abstract]   [Full Text] [Related]  

  • 25. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
    Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis.
    Mettler L; Steinmüller H; Schachner-Wünschmann E
    Hum Reprod; 1991 May; 6(5):694-8. PubMed ID: 1834693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
    Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of GnRH depot analogue in the treatment of uterine fibroids.
    Auber G; Ricci G; Barciulli F; Pregazzi R; D'Ancona RL; Toffoletti FG
    Acta Eur Fertil; 1990; 21(4):185-9. PubMed ID: 2150737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Goserelin--depot preparation of LHRH analogue used in the treatment of endometriosis.
    Shaw RW
    Prog Clin Biol Res; 1990; 323():383-92. PubMed ID: 2137621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells.
    Lamberts SW; Uitterlinden P; Reubi JC; de Jong FH
    Neuroendocrinology; 1989 Feb; 49(2):157-63. PubMed ID: 2524674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of chronic gonadotropin-releasing hormone agonist treatment on serum luteinizing hormone and testosterone concentrations in boars.
    Almond GW; Esbenshade KL; Smith CA; Richards RG
    Am J Vet Res; 1992 Jan; 53(1):22-5. PubMed ID: 1531744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Goserelin depot: an analog of LHRH for the treatment of endometriosis].
    Shaw RW
    Drugs Exp Clin Res; 1990; 16 Suppl():69-75. PubMed ID: 2150504
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of rat ovarian [3H]thymidine uptake by luteinizing hormone-releasing hormone agonists: a possible mechanism for preventing damage by cytotoxic agents.
    Ataya KM; Palmer KC; Blacker CM; Moghissi KS; Mohammad SH
    Cancer Res; 1988 Dec; 48(24 Pt 1):7252-6. PubMed ID: 2973371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.